(Q34587379)

3 August 2017

Pharmacological management of Cushing's syndrome: an update (English)

1 reference

3 August 2017

1 reference

1 reference

Cuong Nguyen Dang

1

1 reference

PubMed ID

18209872

3 August 2017

Peter Trainer

series ordinal

2

1 reference

3 August 2017

1 November 2007

1 reference

Arquivos Brasileiros de Endocrinologia e Metabologia

3 August 2017

1 reference

3 August 2017

51

1 reference

3 August 2017

8

1 reference

3 August 2017

1339-1348

1 reference

Aberrant expression of hormone receptors in adrenal Cushing's syndrome

3 August 2017

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Clinical application of a new test of pituitary reserve

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Metyrapone Is Useful Only as Adjunctive Therapy in Cushing's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

The endocrine effects of ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Ketoconazole treatment in Cushing's syndrome: experience in 34 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Fatal liver failure due to ketoconazole treatment of a girl with Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Ketoconazole-associated hepatic injury. A clinicopathological study of 55 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Effect of 1-)0-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane on adrenocorticotropic hormone-induced steroidogenesis in various preparations in vitro of dog adrenal cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Complexing of DDT and o,p'DDD with adrenal cytochrome P-450 hydroxylating systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Adrenal cortical carcinoma. Results of treatment with o,p'DDD in 138 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

AN EFFECT OF O,P'-DDD ON THE EXTRA-ADRENAL METABOLISM OF CORTISOL IN MAN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Hepatic microsomal enzyme induction and adrenal crisis due to o,p'DDD therapy for metastatic adrenocortical carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Inhibition of adrenal corticosteroid synthesis by aminoglutethimide: studies of the mechanism of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Aminoglutethimide and ketoconazole: historical perspectives and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Aminoglutethimide in the treatment of Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Effect of aminoglutethimide on urinary cortisol and cortisol metabolites in adolescents with Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Medical therapy for Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Cortisol, aldosterone, cortisol precursor, androgen and endogenous ACTH concentrations in dogs with pituitary-dependant hyperadrenocorticism treated with trilostane

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Influence of sedation on mortality in critically ill multiple trauma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Different inhibitory effect of etomidate and ketoconazole on the human adrenal steroid biosynthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Long-term etomidate and adrenocortical suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Nonhypnotic low-dose etomidate for rapid correction of hypercortisolaemia in cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Adrenocorticotropin-Secreting Pituitary Adenomas Originate from the Anterior or the Intermediate Lobe in Cushing's Disease: Differences in the Regulation of Hormone Secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Bromocriptine-responsive Cushing's disease associated with anterior pituitary corticotroph hyperplasia or normal pituitary gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Beneficial effects of high daily dose bromocriptine treatment in Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

The medical management of Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Macroprolactinoma associated with Cushing's disease, successfully treated with cabergoline

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Cabergoline plus lanreotide for ectopic Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Dopamine receptor expression and function in corticotroph ectopic tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Pre-operative medical therapy with rosiglitazone in two patients with newly diagnosed pituitary-dependent Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Ineffectiveness of rosiglitazone therapy in Nelson's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Opportunities in somatostatin research: biological, chemical and therapeutic aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Cell specific expression of the sst2A and sst5 somatostatin receptors in the rat anterior pituitary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Central Nervous System Regulation of Adrenocorticotropin Secretion: Role of Somatostatins*

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Release of pro-opiomelanocortin-derived peptides from the pars intermedia and pars distalis of the rat pituitary: effect of corticotrophin-releasing factor and somatostatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Suppression of ACTH Secretion by Synthetic MSH-Release Inhibiting Factor PRO-LEU-GLY-NH2in Addison's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

The pituitary-adrenal response to CRF-41 is unaltered by intravenous somatostatin in normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Inhibition by somatostatin of ACTH secretion in Nelson's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Long-term treatment of Nelson's syndrome by octreotide: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Octreotide exerts different effects in vivo and in vitro in Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Regulation of mouse somatostatin receptor type 2 gene expression by glucocorticoids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Alternative promoter usage and tissue specific expression of the mouse somatostatin receptor 2 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

The effect of cyproheptadine and/or bromocriptine on plasma ACTH levels in patients cured of Cushing's disease by bilateral adrenalectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Sodium valproate and metyrapone for pituitary-dependent Cushing's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Acute promyelocytic leukemia: evolving therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Retinoic acid prevents experimental Cushing syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Retinoic acid as a novel medical therapy for Cushing's disease in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

Mifepristone: treatment of Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800020

10.1590/S0004-27302007000800020

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

18209872